Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer
Metrics: PDF 4722 views | HTML 4634 views | ?
Meng Zhou1,*, Zhiyong Diao2,*, Xiaolong Yue3,*, Yang Chen1, Hengqiang Zhao1, Liang Cheng1, Jie Sun1
1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, PR China
2Department of Plastic Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, PR China
3Medical Oncology Department, Affiliated Tumor Hospital, Harbin Medical University, Harbin, 150001, PR China
*These authors contributed equally to this work
Jie Sun, email: firstname.lastname@example.org
Liang Cheng, email: email@example.com
Keywords: competing endogenous RNAs, ceRNA network, early diagnosis, long non-coding RNAs, pancreatic cancer
Received: June 21, 2016 Accepted: July 19, 2016 Published: July 28, 2016
It is increasing evidence that ceRNA activity of long non-coding RNAs (lncRNAs) played critical roles in both normal physiology and tumorigenesis. However, functional roles and regulatory mechanisms of lncRNAs as ceRNAs in pancreatic ductal adenocarcinoma (PDAC), and their potential implications for early diagnosis remain unclear. In this study, we performed a genome-wide analysis to investigate potential lncRNA-mediated ceRNA interplay based on “ceRNA hypothesis”. A dysregulated lncRNA-associated ceRNA network (DLCN) was constructed by utilizing sample-matched miRNA, lncRNA and mRNA expression profiles in PDAC and normal samples in combination with miRNA regulatory network. The results of network analysis uncovered seven novel lncRNAs as functional ceRNAs whose aberrant expression will result in the extensive variation in tumorigenic or tumor-suppressive gene expression through DLCN at the post-transcriptional level contributing to PDAC. Therefore, we developed a 7-lncRNA signature (termed LncRisk-7) based on the expression data of seven lncRNAs and SVM algorithm as a novel diagnostic tool to improve early diagnosis of PDAC. The LncRisk-7 achieved high performance in distinguishing PDAC patients from nonmalignant pancreas samples in the discovery cohort and was further confirmed in another two independent validation cohorts. Functional analysis demonstrated that seven lncRNA biomarkers act as ceRNAs involving the regulation of cell death, cell adhesion and cell cycle. This study will help to improve our understanding of the lncRNA-mediated ceRNA regulatory mechanisms in the pathogenesis of PDAC and provide novel lncRNAs as candidate diagnostic biomarkers or potential therapeutic targets.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.